XTX Markets’s Viking Therapeutics VKTX Stock Holding History

XTX Markets’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15,397	Closed	-$111K	–	189
2020 Q2	$111K	Buy	+15,397	New	+$102K	0.38%	109

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

XTX Markets's VKTX Position: Q3 2020 in Review

XTX Markets sold out of Viking Therapeutics (VKTX) in Q3 2020, closing a stake of 15,397 shares — an estimated $111K sold.

XTX Markets first reported a position in VKTX in Q2 2020 and held it in 1 quarter. The position peaked at $111K in Q2 2020. 140 funds tracked by Wall St. Rank hold VKTX as of Q3 2020.

XTX Markets reported no remaining Viking Therapeutics position as of Q3 2020 after selling out during the quarter.
XTX Markets sold 15,397 Viking Therapeutics shares in Q3 2020, an estimated $111K.
XTX Markets first reported a position in Viking Therapeutics in Q2 2020 and held it in 1 quarter.
XTX Markets's Viking Therapeutics position peaked at $111K in Q2 2020.
140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2020.

Based on XTX Markets's 13F filing for Q3 2020, filed 29 Oct 2020.